Table 1

Demographics and disease characteristics of the 202 patients of this study

Number of patients 202
Age (years)38.2±12.6
Gender (male)147 (72.8%)
HLA-B27177 (88.9%)
Smoking status (current)35 (17.3%)
Smoking status (ever)39 (19.3%)
Alcohol27 (13.4%)
Disease duration (months)87.5±86.6
Uric acid (umol/L)380.2±107.7
BASFI (0–10)1.8±2.2
Axial involvement (any)181 (89.6%)
Peripheral involvement (any)104 (51.5%)
Axial involvement (only)103 (51.0%)
Peripheral involvement (only)25 (12.4%)
Mixed (axial and peripheral involvement)84 (41.6%)
Enthesitis involvement25 (12.4%)
Dactylitis9 (4.5%)
Uveitis35 (17.3%)
Psoriasis10 (5.0%)
IBD4 (2.0%)
Diarrhoea21 (10.4%)
NSAID (ever)107 (53.0%)
Corticosteroids (past)27 (13.4%)
Conventional synthetic DMARDs (past)49 (24.3%)
TNFi (past)21 (10.4%)
Conventional synthetic DMARDs (onset)53 (26.2%)
TNFi (onset)63 (31.2%)
  • All results are presented as mean±SD for continuous variables and percentages for categorical variables.

  • ASDAS, Ankylosing Spondylitis Disease Activity Score-CRP; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; DMARDs, disease-modifying antirheumatic drugs; HLA-B27, human leucocyte antigen B27; IBD, inflammatory bowel disease; NSAID, non-steroidal anti-inflammatory drug; TNFi, tumour necrosis factor inhibitor.